ArticleFrontiers in genetics2019
Amplification of the
Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Targeting CD24 Activates Macrophages to Reduce Tumor Burden in Preclinical Models of Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Silencing CD24 Inhibits Proliferation, Migration, and Chemoresistance in Triple-Negative Breast Cancer Cells.Pharmaceutical research · 2026Article
- Role of Liquid Biopsy in Oral Premalignant and Malignant Lesions: Correlation with CD24 and CD44 Expression in Early Diagnosis of Oral Cancer.Journal of maxillofacial and oral surgery · 2025Article
- Unveiling patterns in spatial transcriptomics data: a novel approach utilizing graph attention autoencoder and multiscale deep subspace clustering network.GigaScience · 2025Article
- Hsp70 regulates CD24 expression and promotes metastasis and invasion of lung cancer via the MAPK/ERK signaling pathway.Frontiers in oncology · 2025Article
- "Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity.Cancer communications (London, England) · 2024Review
- CD24-Siglec interactions in inflammatory diseases.Frontiers in immunology · 2023Review
- CD24 May Serve as an Immunotherapy Target in Triple-Negative Breast Cancer by Regulating the Expression of PD-L1.Breast cancer (Dove Medical Press) · 2023Article
- DeepST: identifying spatial domains in spatial transcriptomics by deep learning.Nucleic acids research · 2022Article
- Role of adipose tissue-derived cytokines in the progression of inflammatory breast cancer in patients with obesity.Lipids in health and disease · 2022Article
- CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma.Biomedicines · 2022Article
- The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas.Molecular oncology · 2022Article
- Predictors of the CD24/CD11b Biomarker among Healthy Subjects.Journal of personalized medicine · 2021Article
- Article
- Mechanisms of Multidrug Resistance in Cancer Chemotherapy.International journal of molecular sciences · 2020Review
- A CD24-p53 axis contributes to African American prostate cancer disparities.The Prostate · 2020Article
- Identification ofFrontiers in bioengineering and biotechnology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.